

Himanshu Nagar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8321199/publications.pdf>

Version: 2024-02-01

29
papers

548
citations

840776

11
h-index

642732

23
g-index

29
all docs

29
docs citations

29
times ranked

1051
citing authors

#	ARTICLE	IF	CITATIONS
1	Mast cell tryptase may modulate endothelial cell phenotype in healing myocardial infarcts. <i>Journal of Pathology</i> , 2005, 205, 102-111.	4.5	82
2	Cancer and COVID-19 – potentially deleterious effects of delaying radiotherapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 332-334.	27.6	68
3	Local-Regional Recurrence With and Without Radiation Therapy After Neoadjuvant Chemotherapy and Mastectomy for Clinically Staged T3N0 Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 782-787.	0.8	64
4	Trends in the Use of Stereotactic Body Radiotherapy for Treatment of Prostate Cancer in the United States. <i>JAMA Network Open</i> , 2020, 3, e1920471.	5.9	61
5	Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non-Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database. <i>Journal of Thoracic Oncology</i> , 2017, 12, 302-313.	1.1	59
6	Omission of Adjuvant Radiotherapy in the Elderly Breast Cancer Patient: Missed Opportunity?. <i>Clinical Breast Cancer</i> , 2018, 18, 418-431.	2.4	23
7	Impact of Oncotype DX Recurrence Score in the Management of Breast Cancer Cases. <i>Clinical Breast Cancer</i> , 2014, 14, 182-190.	2.4	18
8	Trends in Diagnosis and Disparities in Initial Management of High-Risk Prostate Cancer in the US. <i>JAMA Network Open</i> , 2020, 3, e2014674.	5.9	18
9	The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies. <i>Transplantation</i> , 2017, 101, e34-e38.	1.0	14
10	The State of Surgical Axillary Management and Adjuvant Radiotherapy for Early-stage Invasive Breast Cancer in the Modern Era. <i>Clinical Breast Cancer</i> , 2018, 18, e477-e493.	2.4	14
11	Adjuvant Pelvic Radiation Therapy±Vaginal Brachytherapy in Patients With High-risk Stage I or Stage II Uterine Papillary Serous, Clear Cell, and High-grade Endometrioid Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 335-339.	1.3	13
12	Disease-Free Survival According to the Use of Postmastectomy Radiation Therapy After Neoadjuvant Chemotherapy. <i>Clinical Breast Cancer</i> , 2015, 15, 128-134.	2.4	12
13	Deep learning-based synthetic CT generation for MR-only radiotherapy of prostate cancer patients with 0.35T MRI linear accelerator. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 93-104.	1.9	12
14	Active Surveillance for Men with Intermediate Risk Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 115-121.	0.4	12
15	Older Patients With Early-stage Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 300-305.	1.3	10
16	68Ga-PSMA-HBED-CC PET/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: A prospective single-institutional study. <i>Translational Oncology</i> , 2022, 15, 101242.	3.7	10
17	Administration of Concurrent Vaginal Brachytherapy During Chemotherapy for Treatment of Endometrial Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 665-669.	0.8	9
18	Ductal Carcinoma in Situ in Young Women: Increasing Rates of Mastectomy and Variability in Endocrine Therapy Use. <i>Annals of Surgical Oncology</i> , 2021, 28, 6083-6096.	1.5	9

#	ARTICLE	IF	CITATIONS
19	Is There a Tradeoff in Using Modified High Tangent Field Radiation for Treating an Undissected Node-Positive Axilla?. <i>Clinical Breast Cancer</i> , 2014, 14, 109-113.	2.4	8
20	Hypofractionated Postoperative Radiotherapy for Prostate Cancer: Is the Field Ready Yet?. <i>European Urology Open Science</i> , 2020, 22, 9-16.	0.4	8
21	Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores. <i>Breast Cancer Research</i> , 2018, 20, 26.	5.0	5
22	Challenging the Norm: What Level of Evidence Is Necessary to Adopt Postprostatectomy Hypofractionated Radiation Therapy?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 297-298.	0.8	4
23	Quantifying the impact of SpaceOAR hydrogel on inter-fractional rectal and bladder dose during 0.35 Gy MR-guided prostate adaptive radiotherapy. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 49-58.	1.9	4
24	Trends in Androgen Deprivation Use in Men With Intermediate-Risk Prostate Cancer Who Underwent Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2022, 7, 100904.	1.2	4
25	An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 278-289.	0.8	4
26	Natural history of lower urinary tract symptoms among men undergoing stereotactic body radiation therapy for prostate cancer with and without a Rectal Hydrogel Spacer. <i>World Journal of Urology</i> , 2022, 40, 1143-1150.	2.2	3
27	Re: Early Results of Unilateral Prostatic Artery Embolization as a Focal Therapy in Patients with Prostate Cancer under Active Surveillance: Cancer Prostate Embolization, a Pilot Study. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 1243-1244.	0.5	0
28	Prostate SBRT Dose Escalation (9 Gy, 13.3 Gy, 24 Gy): Are We Making Progress?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 110-112.	0.8	0
29	Time management: Improving the timing of post-prostatectomy radiotherapy, clinical trials, and knowledge translation. <i>Clinical and Translational Radiation Oncology</i> , 2021, 31, 21-27.	1.7	0